A Role for Mitogen- and Stress-Activated Kinase 1 in L-DOPA–Induced Dyskinesia and ∆FosB Expression

Biological Psychiatry

Volumn 79, Issue 5, 2016, Pages 362-371

  Feyder, Michael ^a   Södersten, Erik ^a,b   Santini, Emanuela ^a   Vialou, Vincent ^c,d   LaPlant, Quincey ^c   Watts, Emily L ^c   Spigolon, Giada ^a   Hansen, Klaus ^b   Caboche, Jocelyne ^d   Nestler, Eric J ^c   Fisone, Gilberto ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d INSERM   (France)

Author keywords

Dopamine D1 receptor; Histone; Medium spiny neurons; Mouse; Parkinson's disease; Striatum

Indexed keywords

BENSERAZIDE; HISTONE H3; MITOGEN ACTIVATED PROTEIN KINASE 1; STRESS ACTIVATED PROTEIN KINASE 1; TRANSCRIPTION FACTOR FOSB; ANTIPARKINSON AGENT; HISTONE; LEVODOPA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN AND STRESS-ACTIVATED PROTEIN KINASE 1; OXIDOPAMINE; PROTEIN C FOS; S6 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYLINDER TEST; GENE OVEREXPRESSION; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; LEVODOPA-INDUCED DYSKINESIA; MALE; MOUSE; NONHUMAN; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION INITIATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; COMPLICATION; DRUG EFFECTS; DYSKINESIA; KNOCKOUT MOUSE; METABOLISM; NEOSTRIATUM; NERVE CELL; PHOSPHORYLATION;

ANIMALS; ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HISTONES; LEVODOPA; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOSTRIATUM; NEURONS; OXIDOPAMINE; PARKINSON DISEASE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-FOS; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA;

EID: 84977649867     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2014.07.019     Document Type: Article

References (48)

1. 1 Obeso, J.A., Olanow, C.W., Nutt, J.G., Levodopa motor complications in Parkinson's disease. Trends Neurosci 23 (2000), S2–S7.
2. 2 Guigoni, C., Aubert, I., Li, Q., Gurevich, V.V., Benovic, J.L., Ferry, S., et al. Pathogenesis of levodopa-induced dyskinesia: Focus on D1 and D3 dopamine receptors. Parkinsonism Relat Disord 11:suppl 1 (2005), S25–S29.
3. 3 Aubert, I., Guigoni, C., Hakansson, K., Li, Q., Dovero, S., Barthe, N., et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57 (2005), 17–26.
4. 4 Feyder, M., Bonito-Oliva, A., Fisone, G., L-DOPA-induced dyskinesia and abnormal signaling in striatal medium spiny neurons: Focus on dopamine D1 receptor-mediated transmission. Front Behav Neurosci, 5, 2011, 71.
5. 5 Darmopil, S., Martin, A.B., De Diego, I.R., Ares, S., Moratalla, R., Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol Psychiatry 66 (2009), 603–613.
6. 6 Gerfen, C.R., Miyachi, S., Paletzki, R., Brown, P., D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci 22 (2002), 5042–5054.
7. 7 Lebel, M., Chagniel, L., Bureau, G., Cyr, M., Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat. Neurobiol Dis 38 (2010), 59–67.
8. 8 Santini, E., Alcacer, C., Cacciatore, S., Heiman, M., Herve, D., Greengard, P., et al. L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J Neurochem 108 (2009), 621–633.
9. 9 Santini, E., Sgambato-Faure, V., Li, Q., Savasta, M., Dovero, S., Fisone, G., et al. Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia. PLoS One, 5, 2010, e12322.
10. 10 Santini, E., Valjent, E., Usiello, A., Carta, M., Borgkvist, A., Girault, J.A., et al. Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J Neurosci 27 (2007), 6995–7005.
11. 11 Westin, J.E., Vercammen, L., Strome, E.M., Konradi, C., Cenci, M.A., Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry 62 (2007), 800–810.
12. 12 Brami-Cherrier, K., Valjent, E., Herve, D., Darragh, J., Corvol, J.C., Pages, C., et al. Parsing molecular and behavioral effects of cocaine in mitogen- and stress-activated protein kinase-1-deficient mice. J Neurosci 25 (2005), 11444–11454.
13. 13 Cheung, P., Tanner, K.G., Cheung, W.L., Sassone-Corsi, P., Denu, J.M., Allis, C.D., Synergistic coupling of histone H3 phosphorylation and acetylation in response to epidermal growth factor stimulation. Mol Cell 5 (2000), 905–915.
14. 14 Clayton, A.L., Rose, S., Barratt, M.J., Mahadevan, L.C., Phosphoacetylation of histone H3 on c-fos- and c-jun-associated nucleosomes upon gene activation. EMBO J 19 (2000), 3714–3726.
15. 15 Crosio, C., Heitz, E., Allis, C.D., Borrelli, E., Sassone-Corsi, P., Chromatin remodeling and neuronal response: Multiple signaling pathways induce specific histone H3 modifications and early gene expression in hippocampal neurons. J Cell Sci 116 (2003), 4905–4914.
16. 16 Thomson, S., Clayton, A.L., Mahadevan, L.C., Independent dynamic regulation of histone phosphorylation and acetylation during immediate-early gene induction. Mol Cell 8 (2001), 1231–1241.
17. 17 Andersson, M., Hilbertson, A., Cenci, M.A., Striatal fosB expression is causally linked with L-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol Dis 6 (1999), 461–474.
18. 18 Doucet, J.P., Nakabeppu, Y., Bedard, P.J., Hope, B.T., Nestler, E.J., Jasmin, B.J., et al. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum. Eur J Neurosci 8 (1996), 365–381.
19. 19 Lindgren, H.S., Rylander, D., Iderberg, H., Andersson, M., O'Sullivan, S.S., Williams, D.R., et al. Putaminal upregulation of FosB/DeltaFosB-like immunoreactivity in Parkinson's disease patients with dyskinesia. J Parkinsons Dis 1 (2011), 347–357.
20. 20 Pavon, N., Martin, A.B., Mendialdua, A., Moratalla, R., ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry 59 (2006), 64–74.
21. 21 Nestler, E.J., Review. Transcriptional mechanisms of addiction: Role of deltaFosB. Philos Trans R Soc Lond B Biol Sci 363 (2008), 3245–3255.
22. 22 Berton, O., Guigoni, C., Li, Q., Bioulac, B.H., Aubert, I., Gross, C.E., et al. Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease. Biol Psychiatry 66 (2009), 554–561.
23. 23 Cao, X., Yasuda, T., Uthayathas, S., Watts, R.L., Mouradian, M.M., Mochizuki, H., et al. Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements. J Neurosci 30 (2010), 7335–7343.
24. 24 Fasano, S., Bezard, E., D'Antoni, A., Francardo, V., Indrigo, M., Qin, L., et al. Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-DOPA-induced dyskinesia. Proc Natl Acad Sci U S A 107 (2010), 21824–21829.
25. 25 Wiggin, G.R., Soloaga, A., Foster, J.M., Murray-Tait, V., Cohen, P., Arthur, J.S., MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts. Mol Cell Biol 22 (2002), 2871–2881.
26. 26 Chen, J., Kelz, M.B., Zeng, G., Sakai, N., Steffen, C., Shockett, P.E., et al. Transgenic animals with inducible, targeted gene expression in brain. Mol Pharmacol 54 (1998), 495–503.
27. 27 Muschamp, J.W., Nemeth, C.L., Robison, A.J., Nestler, E.J., Carlezon, W.A. Jr., DeltaFosB enhances the rewarding effects of cocaine while reducing the pro-depressive effects of the kappa-opioid receptor agonist U50488. Biol Psychiatry 71 (2012), 44–50.
28. 28 Peakman, M.C., Colby, C., Perrotti, L.I., Tekumalla, P., Carle, T., Ulery, P., et al. Inducible, brain region-specific expression of a dominant negative mutant of c-Jun in transgenic mice decreases sensitivity to cocaine. Brain Res 970 (2003), 73–86.
29. 29 Kelz, M.B., Chen, J., Carlezon, W.A. Jr., Whisler, K., Gilden, L., Beckmann, A.M., et al. Expression of the transcription factor deltaFosB in the brain controls sensitivity to cocaine. Nature 401 (1999), 272–276.
30. 30 McClung, C.A., Nestler, E.J., Regulation of gene expression and cocaine reward by CREB and DeltaFosB. Nat Neurosci 6 (2003), 1208–1215.
31. 31 Gong, S., Zheng, C., Doughty, M.L., Losos, K., Didkovsky, N., Schambra, U.B., et al. A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 425 (2003), 917–925.
32. 32 Lundblad, M., Usiello, A., Carta, M., Hakansson, K., Fisone, G., Cenci, M.A., Pharmacological validation of a mouse model of L-DOPA-induced dyskinesia. Exp Neurol 194 (2005), 66–75.
33. 33 Santini, E., Feyder, M., Gangarossa, G., Bateup, H.S., Greengard, P., Fisone, G., Dopamine- and cAMP-regulated phosphoprotein of 32-kDa (DARPP-32)-dependent activation of extracellular signal-regulated kinase (ERK) and mammalian target of rapamycin complex 1 (mTORC1) signaling in experimental parkinsonism. J Biol Chem 287 (2012), 27806–27812.
34. 34 Lobo, M.K., Zaman, S., Damez-Werno, D.M., Koo, J.W., Bagot, R.C., DiNieri, J.A., et al. DeltaFosB induction in striatal medium spiny neuron subtypes in response to chronic pharmacological, emotional, and optogenetic stimuli. J Neurosci 33 (2013), 18381–18395.
35. 35 Valjent, E., Corvol, J.C., Pages, C., Besson, M.J., Maldonado, R., Caboche, J., Involvement of the extracellular signal-regulated kinase cascade for cocaine-rewarding properties. J Neurosci 20 (2000), 8701–8709.
36. 36 Franklin, K.B.J., Paxinos, G., The Mouse Brain in Stereotaxic Coordinates. 1997, Academic Press, San Diego.
37. 37 Schuster, S., Nadjar, A., Guo, J.T., Li, Q., Ittrich, C., Hengerer, B., et al. The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease. J Neurosci 28 (2008), 4311–4316.
38. 38 Thomas, G.M., Huganir, R.L., MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci 5 (2004), 173–183.
39. 39 Brami-Cherrier, K., Roze, E., Girault, J.A., Betuing, S., Caboche, J., Role of the ERK/MSK1 signalling pathway in chromatin remodelling and brain responses to drugs of abuse. J Neurochem 108 (2009), 1323–1335.
40. 40 Gehani, S.S., Agrawal-Singh, S., Dietrich, N., Christophersen, N.S., Helin, K., Hansen, K., Polycomb group protein displacement and gene activation through MSK-dependent H3K27me3S28 phosphorylation. Mol Cell 39 (2010), 886–900.
41. 41 Bertran-Gonzalez, J., Bosch, C., Maroteaux, M., Matamales, M., Herve, D., Valjent, E., et al. Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol. J Neurosci 28 (2008), 5671–5685.
42. 42 Clayton, A.L., Mahadevan, L.C., MAP kinase-mediated phosphoacetylation of histone H3 and inducible gene regulation. FEBS Lett 546 (2003), 51–58.
43. 43 Hope, B., Kosofsky, B., Hyman, S.E., Nestler, E.J., Regulation of immediate early gene expression and AP-1 binding in the rat nucleus accumbens by chronic cocaine. Proc Natl Acad Sci U S A 89 (1992), 5764–5768.
44. 44 Li, J., Guo, Y., Schroeder, F.A., Youngs, R.M., Schmidt, T.W., Ferris, C., et al. Dopamine D2-like antagonists induce chromatin remodeling in striatal neurons through cyclic AMP-protein kinase A and NMDA receptor signaling. J Neurochem 90 (2004), 1117–1131.
45. 45 Valjent, E., Bertran-Gonzalez, J., Bowling, H., Lopez, S., Santini, E., Matamales, M., et al. Haloperidol regulates the state of phosphorylation of ribosomal protein S6 via activation of PKA and phosphorylation of DARPP-32. Neuropsychopharmacology 36 (2011), 2561–2570.
46. 46 Gerfen, C.R., Paletzki, R., Worley, P., Differences between dorsal and ventral striatum in Drd1a dopamine receptor coupling of dopamine- and cAMP-regulated phosphoprotein-32 to activation of extracellular signal-regulated kinase. J Neurosci 28 (2008), 7113–7120.
47. 47 Greengard, P., The neurobiology of slow synaptic transmission. Science 294 (2001), 1024–1030.
48. 48 Santini, E., Heiman, M., Greengard, P., Valjent, E., Fisone, G., Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia. Sci Signal, 2, 2009 ra36.